In order to deliver a personalised, responsive service and to improve the site, we remember and store information about how you use it. This is done using simple text files called cookies which sit on your computer. By continuing to use this site and access its features, you are consenting to our use of cookies. To find out more about the way drugeruptiondata.com uses cookies please read our 'Cookie Policy'.
PREGNANCY: Based on findings from animal studies of other drugs that enhance GABAergic inhibition, ZULRESSO may cause fetal harm. There are no available data on ZULRESSO use in pregnant women to determine a drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes.
Pregnancy: May cause fetal harm.
Avoid use in patients with end stage renal disease
WARNING: EXCESSIVE SEDATION AND SUDDEN LOSS OF CONSCIOUSNESS
PATIENTS ARE AT RISK OF EXCESSIVE SEDATION OR SUDDEN LOSS OF CONSCIOUSNESS DURING ADMINISTRATION OF ZULRESSO (BREXANOLONE). BECAUSE OF THE RISK OF SERIOUS HARM, PATIENTS MUST BE MONITORED FOR EXCESSIVE SEDATION AND SUDDEN LOSS OF CONSCIOUSNESS AND HAVE CONTINUOUS PULSE OXIMETRY MONITORING. PATIENTS MUST BE ACCOMPANIED DURING INTERACTIONS WITH THEIR CHILD(REN). ZULRESSO IS AVAILABLE ONLY THROUGH A RESTRICTED PROGRAM CALLED THE ZULRESSO REMS.
See full prescribing information for complete boxed warning
Please login to view the rest of this drug profile.